Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure (CONCERT-HF)

• ClinicalTrials.gov Identifier: NCT02501811
• Recruitment Status: Completed
• First Posted: July 17, 2015
• Last Update Posted: October 27, 2020
• Sponsor: The University of Texas Health Science Center, Houston
• Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
• Information provided by (Responsible Party): Barry R Davis, The University of Texas Health Science Center, Houston

Study Description

Brief Summary:

This is a phase II, randomized, placebo-controlled clinical trial designed to assess feasibility, safety, and effect of autologous bone marrow-derived mesenchymal stem cells (MSCs) and c-kit+ cells both alone and in combination (Combo), compared to placebo (cell-free Plasmalyte-A medium) as well as each other, administered by transendocardial injection in subjects with ischemic cardiomyopathy.

Condition or disease	Intervention/treatment	Phase
Ischemic Cardiomyopathy	Biological: Mesenchymal Stem Cells (MSC); Biological: c-kit+ cells; Biological: Placebo (Plasmalyte A)	Phase 2

Detailed Description:

This is a randomized, placebo-controlled clinical trial designed to evaluate the feasibility, safety, and effect of Combo, MSCs alone, and c-kit+ cells alone compared with placebo as well as each other in subjects with heart failure of ischemic etiology. Following a successful lead-in phase, a total of one hundred forty-four (144) subjects will be randomized (1:1:1:1) to receive Combo, MSCs, c-kit+ cells, or placebo. After randomization, baseline imaging, relevant harvest procedures, and study product injection, subjects will be followed up at 1 day, 1 week, 1 month, 3 months, 6 months and 12 months post study product injection. All subjects will receive study product injection (cells or placebo) using the NOGA® XP Mapping and Navigation System. Subjects will have delayed-enhanced magnetic resonance imaging (DEMRI) scans to assess scar size and LV function and structure at baseline and at 6 and 12 months post study product administration. All endpoints will be assessed at the 6 and 12 month visits which will occur 180 ±30 days and 365 ±30 days respectively from the day of study product injection (Day 0). For the purpose of the endpoint analysis and safety evaluations, the Investigators will utilize an "intention-to-treat" study population, however an as treated analysis will also be conducted.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 125 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Phase II, Randomized, Placebo-Controlled Study of the Safety, Feasibility, and Efficacy of Autologous Mesenchymal Stem Cells and C-kit+ Cardiac Stem Cells, Alone or in Combination, Administered Transendocardially in Subjects With Ischemic Heart Failure
• Study Start Date: October 2015
• Actual Primary Completion Date: June 25, 2020
• Actual Study Completion Date: July 22, 2020

Arms and Interventions

Arm	Intervention/treatment
Experimental: Mesenchymal Stem Cells (MSC); Target dose of 150 million MSCs	Biological: Mesenchymal Stem Cells (MSC); 15 transendocardial injections of 0.4ml MSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
Experimental: c-kit+ cells; Target dose of 5 million c-kit+ cells	Biological: c-kit+ cells; 15 transendocardial injections of 0.4ml c-kit+ cells administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
Experimental: Combination Cells (MSC and c-kit+ cells); Target dose of 150 million MSCs and 5 million c-kit+ cells	Biological: Mesenchymal Stem Cells (MSC); 15 transendocardial injections of 0.4ml MSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure); Biological: c-kit+ cells; 15 transendocardial injections of 0.4ml c-kit+ cells administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
Placebo Comparator: Placebo (Plasmalyte A); Plasmalyte A	Biological: Placebo (Plasmalyte A); 15 transendocardial injections of 0.4ml placebo administered to the left ventricle via NOGA Myostar injection catheter (single procedure); Other Name: Plasmalyte A

Outcome Measures

Primary Outcome Measures :

1. Left Ventricular Ejection Fraction (LVEF) [ Time Frame: Assessed as a trajectory (baseline, 6 months, and 12 months) ]
   Change in left ventricular ejection fraction as assessed via cardiac MRI
2. Left Ventricular Ejection Fraction (LVEF) [ Time Frame: Baseline to 6 months ]
   Change in left ventricular ejection fraction as assessed via cardiac MRI
3. Left Ventricular Ejection Fraction (LVEF) [ Time Frame: Baseline to 12 months ]
   Change in left ventricular ejection fraction as assessed via cardiac MRI
4. Global Strain (HARP MRI) [ Time Frame: Assessed as a trajectory (baseline, 6 months, and 12 months) ]
   Change in global circumferential strain as assessed via cardiac MRI
5. Global Strain (HARP MRI) [ Time Frame: Baseline to 6 months ]
   Change in global circumferential strain as assessed via cardiac MRI
6. Global Strain (HARP MRI) [ Time Frame: Baseline to 12 months ]
   Change in global circumferential strain as assessed via cardiac MRI
7. Regional Strain (HARP MRI) [ Time Frame: Assessed as a trajectory (baseline, 6 months, and 12 months) ]
   Change in regional longitudinal strain as assessed via cardiac MRI
8. Regional Strain (HARP MRI) [ Time Frame: Baseline to 6 months ]
   Change in regional longitudinal strain as assessed via cardiac MRI
9. Regional Strain (HARP MRI) [ Time Frame: Baseline to 12 months ]
   Change in regional longitudinal strain as assessed via cardiac MRI
10. Left Ventricular End Diastolic Volume Index (LVEDVI) [ Time Frame: Assessed as a trajectory (baseline, 6 months, and 12 months) ]
    Change in left ventricular end diastolic volume index as measured via cardiac MRI
11. Left Ventricular End Diastolic Volume Index (LVEDVI) [ Time Frame: Baseline to 6 months ]
    Change in left ventricular end diastolic volume index as measured via cardiac MRI
12. Left Ventricular End Diastolic Volume Index (LVEDVI) [ Time Frame: Baseline to 12 months ]
    Change in left ventricular end diastolic volume index as measured via cardiac MRI
13. Left Ventricular End Systolic Volume Index (LVESVI) [ Time Frame: Assessed as a trajectory (baseline, 6 months, 12 months) ]
    Change in left ventricular end systolic volume index as assessed via cardiac MRI
14. Left Ventricular End Systolic Volume Index (LVESVI) [ Time Frame: Baseline to 6 months ]
    Change in left ventricular end systolic volume index as assessed via cardiac MRI
15. Left Ventricular End Systolic Volume Index (LVESVI) [ Time Frame: Baseline to 12 months ]
    Change in left ventricular end systolic volume index as assessed via cardiac MRI
16. Left Ventricular Sphericity Index [ Time Frame: Assessed as a trajectory (baseline, 6 months, and 12 months) ]
    Change in left ventricular sphericity as assessed via cardiac MRI
17. Left Ventricular Sphericity Index [ Time Frame: Baseline to 6 months ]
    Change in left ventricular sphericity as assessed via cardiac MRI
18. Left Ventricular Sphericity Index [ Time Frame: Baseline to 12 months ]
    Change in left ventricular sphericity as assessed via cardiac MRI
19. Infarct/scar Volume (DEMRI) [ Time Frame: Assessed as a trajectory (baseline, 6 months, and 12 months) ]
    Change in infarct/scar volume as assessed via cardiac MRI
20. Infarct/scar Volume (DEMRI) [ Time Frame: Baseline to 6 months ]
    Change in infarct/scar volume as assessed via cardiac MRI
21. Infarct/scar Volume (DEMRI) [ Time Frame: Baseline to 12 months ]
    Change in infarct/scar volume as assessed via cardiac MRI
22. Maximal Oxygen Consumption (VO2 max) [ Time Frame: Assessed as a trajectory (baseline, 6 months, and 12 months) ]
    Change in maximal oxygen consumption (V02 max) as assessed via treadmill
23. Maximal Oxygen Consumption (VO2 max) [ Time Frame: Baseline to 6 months ]
    Change in maximal oxygen consumption (V02 max) as assessed via treadmill
24. Maximal Oxygen Consumption (VO2 max) [ Time Frame: Baseline to 12 months ]
    Change in maximal oxygen consumption (V02 max) as assessed via treadmill
25. Exercise Tolerance [ Time Frame: Assessed as a trajectory (baseline, 6 months, and 12 months) ]
    Change in exercise tolerance as assessed via the 6 minute walk test
26. Exercise Tolerance [ Time Frame: Baseline to 6 months ]
    Change in exercise tolerance as assessed via the 6 minute walk test
27. Exercise Tolerance [ Time Frame: Baseline to 12 months ]
    Change in exercise tolerance as assessed via the 6 minute walk test
28. Minnesota Living with Heart Failure Questionnaire (MHLFQ) Score [ Time Frame: Assessed as a trajectory (baseline, 6 months, and 12 months) ]
    Change in Minnesota Living with Heart Failure Questionnaire (MHLFQ) score
29. Minnesota Living with Heart Failure Questionnaire (MHLFQ) Score [ Time Frame: Baseline to 6 months ]
    Change in Minnesota Living with Heart Failure Questionnaire (MHLFQ) score
30. Minnesota Living with Heart Failure Questionnaire (MHLFQ) Score [ Time Frame: Baseline to 12 months ]
    Change in Minnesota Living with Heart Failure Questionnaire (MHLFQ) score
31. N-Terminal pro-Brain Natriuretic Peptide (NT-proBNP) [ Time Frame: Assessed as a trajectory (baseline, 6 months, and 12 months) ]
    Change in N-Terminal pro-Brain Natriuretic Peptide (NT-proBNP) as measured via blood draw
32. N-Terminal pro-Brain Natriuretic Peptide (NT-proBNP) [ Time Frame: Baseline to 6 months ]
    Change in N-Terminal pro-Brain Natriuretic Peptide (NT-proBNP) as measured via blood draw
33. N-Terminal pro-Brain Natriuretic Peptide (NT-proBNP) [ Time Frame: Baseline to 12 months ]
    Change in N-Terminal pro-Brain Natriuretic Peptide (NT-proBNP) as measured via blood draw
34. Incidence of major adverse cardiac events (MACE) [ Time Frame: Baseline to 6 months ]
    Incidence of adjudicated events including death, hospitalization for worsening heart failure, and/or other exacerbation of heart failure (non-hospitalization)
35. Incidence of major adverse cardiac events (MACE) [ Time Frame: Baseline to 12 months ]
    Incidence of adjudicated events including death, hospitalization for worsening heart failure, and/or other exacerbation of heart failure (non-hospitalization)
36. Incidence of other significant clinical events [ Time Frame: Baseline to 6 months ]
    Incidence of other significant adjudicated clinical events including: non-fatal stroke, non-fatal MI, coronary artery revascularization, ventricular tachycardia/fibrillation, and pericardial tamponade
37. Incidence of other significant clinical events [ Time Frame: Baseline to 12 months ]
    Incidence of other significant adjudicated clinical events including: non-fatal stroke, non-fatal MI, coronary artery revascularization, ventricular tachycardia/fibrillation, and pericardial tamponade
38. Cumulative Days alive and out of hospital for heart failure [ Time Frame: Baseline to 12 months ]
    Days alive and out of hospital during the study evaluation period

Other Outcome Measures:

1. Subjects with events between randomization and study product injection (SPI) that preclude the receipt of product [ Time Frame: Randomization to SPI ]
   Number and percent of subjects with events between randomization and study product injection (SPI) that preclude the subject from receiving product.
2. Subjects who have a failed bone marrow aspiration procedure [ Time Frame: During bone marrow aspiration procedure ]
   Number and percent of subjects who do not successfully undergo bone marrow aspiration
3. Subjects who have a failed endomyocardial biopsy procedure [ Time Frame: During endomyocardial biopsy procedure ]
   Number and percent of subjects who do not successfully undergo endomyocardial biopsy procedure
4. Subject MSC products which failed release criteria [ Time Frame: Harvest to Study Product Injection Procedure ]
   Number and percent of subjects who have MSC products which failed release criteria
5. Subject c-kit+ products which failed release criteria [ Time Frame: Harvest to SPI procedure ]
   Number and percent of subjects who have c-kit+ products which failed release criteria
6. Subjects who receive less than 15 injections during SPI [ Time Frame: During SPI procedure ]
   Number and percent of subjects who received less than 15 injections during SPI
7. Subjects who have at least one cardiac MRI endpoint measure that is uninterpretable [ Time Frame: Baseline to 12 months ]
   Number and percent of subjects who have at least one cardiac MRI endpoint measure that is uninterpretable due to issues related to the device, including, but not limited to, inability to undergo the procedure

Eligibility Criteria

• Ages Eligible for Study: 21 Years to 79 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Be ≥ 21 and <80 years of age
2. Have documented coronary artery disease (CAD) with evidence of myocardial injury, LV dysfunction, and clinical evidence of HF
3. Have a "detectable" area of myocardial injury defined as ≥ 5% LV involvement (infarct volume) and any subendocardial involvement by cMRI
4. Have an EF ≤ 40% by cMRI
5. Be receiving guideline-driven medical therapy for heart failure at stable and tolerated doses for ≥ 1 month prior to consent. For beta-blockade "stable" is defined as no greater than a 50% reduction in dose or no more than a 100% increase in dose.
6. Be a candidate for cardiac catheterization
7. Have NYHA class I, II, or III heart failure symptoms
8. If a female of childbearing potential, be willing to use one form of birth control for the duration of the study, and undergo a pregnancy test at baseline and within 36 hours prior to injection

Exclusion Criteria:

1. Indication for standard-of-care surgery (including valve surgery, placement of left-ventricular assist device, or imminent heart transplantation), coronary artery bypass grafting (CABG) procedure, and/or percutaneous coronary intervention (PCI) for the treatment of ischemic and/or valvular heart disease. Subjects who require or undergo PCI should undergo these procedures a minimum of 3 months in advance of randomization. Subjects who require or undergo CABG should undergo these procedures a minimum of 4 months in advance of randomization. In addition, subjects who develop a need for revascularization following enrollment should undergo revascularization without delay. Indication for imminent heart transplantation is defined as a high likelihood of transplant prior to collection of the 12 month study endpoint. Candidates cannot be UNOS status 1A or 1B, and they must have documented low probability of being transplanted
2. Valvular heart disease including 1) mechanical or bioprosthetic heart valve; or 2) severe (any valve) insufficiency/regurgitation within 12 months of consent
3. Aortic stenosis with valve area ≤ 1.5 cm2
4. History of ischemic or hemorrhagic stroke within 90 days of consent
5. History of a left ventricular remodeling surgical procedure utilizing prosthetic material

6. Presence of a pacemaker and/or implantable cardioverter-defibrillator (ICD) generator with any of the following limitations/conditions:

   • manufactured before the year 2000
   • leads implanted < 6 weeks prior to consent
   • non-transvenous epicardial, or abandoned leads
   • subcutaneous ICDs
   • leadless pacemakers
   • any other condition that, in the judgment of device-trained staff, would deem an MRI contraindicated
7. Pacemaker-dependence with an ICD (Note: pacemaker-dependent candidates without an ICD are not excluded)
8. A cardiac resynchronization therapy (CRT) device implanted less than 3 months prior to consent
9. Other MRI contraindications (e.g. patient body habitus incompatible with MRI)
10. An appropriate ICD firing or anti-tachycardia pacing (ATP) for ventricular fibrillation or ventricular tachycardia within 30 days of consent
11. Ventricular tachycardia ≥ 20 consecutive beats without an ICD within 3 months of consent, or symptomatic Mobitz II or higher degree atrioventricular block without a functioning pacemaker within 3 months of consent
12. Presence of LV thrombus
13. Evidence of active myocarditis
14. Baseline maximal oxygen consumption (VO2 max) greater than 75% of age and gender based predictive values
15. Baseline eGFR <35 ml/min/1.73m2
16. Blood glucose levels (HbA1c) >10%
17. Hematologic abnormality evidenced by hematocrit < 25%, white blood cell < 2,500/ul or platelet count < 100,000/ul
18. Liver dysfunction evidenced by enzymes (AST and ALT) ˃ 3 times the upper limit of normal (ULN)
19. Coagulopathy (INR ≥ 1.3) not due to a reversible cause (e.g., warfarin and/or Factor Xa inhibitors). Subjects who cannot be withdrawn from anticoagulation will be excluded.
20. HIV and/or active hepatitis B virus (HBV) or hepatitis C virus (HCV)
21. Allergy to radiographic contrast material that cannot adequately be managed by premedication
22. Known history of anaphylactic reaction to penicillin or streptomycin
23. Received gene or cell-based therapy from any source within the previous 12 months
24. History of malignancy within 5 years (i.e., subjects with prior malignancy must be disease free for 5 years), excluding basal cell carcinoma and cervical carcinoma in situ which have been definitively treated
25. Condition that limits lifespan to < 1 year
26. History of drug abuse (illegal "street" drugs except marijuana, or prescription medications not being used appropriately for a pre-existing medical condition) or alcohol abuse (≥ 5 drinks/day for ˃ 3 months), or documented medical, occupational, or legal problems arising from the use of alcohol or drugs within the past 24 months
27. Participation in an investigational therapeutic or device trial within 30 days of consent
28. Cognitive or language barriers that prohibit obtaining informed consent or any study elements
29. Pregnancy or lactation or plans to become pregnant in the next 12 months
30. Any other condition that, in the judgment of the Investigator or Sponsor, would impair enrollment, study product administration, or follow-up

Contacts and Locations

Locations

United States, California

Stanford University School of Medicine (Falk Cardiovascular Research Center)

Stanford, California, United States, 94305

United States, Florida

University of Florida-Department of Medicine

Gainesville, Florida, United States, 32610

University of Miami-Interdisciplinary Stem Cell Institute

Miami, Florida, United States, 33101

United States, Indiana

Indiana Center for Vascular Biology and Medicine

Indianapolis, Indiana, United States, 46202

United States, Kentucky

University of Louisville

Louisville, Kentucky, United States, 40202

United States, Minnesota

Minneapolis Heart Institute Foundation

Minneapolis, Minnesota, United States, 55407

United States, Texas

Texas Heart Institute

Houston, Texas, United States, 77030

Sponsors and Collaborators

The University of Texas Health Science Center, Houston

National Heart, Lung, and Blood Institute (NHLBI)

Investigators

• Study Chair: Robert Simari, MD; CCTRN Steering Committee Chair

More Information

Additional Information:

Cardiovascular Cell Therapy Research Network 

National Heart, Lung, and Blood Institute 

Information on stem cells from the National Institutes of Health 

Publications:

Hare JM, Bolli R, Cooke JP, Gordon DJ, Henry TD, Perin EC, March KL, Murphy MP, Pepine CJ, Simari RD, Skarlatos SI, Traverse JH, Willerson JT, Szady AD, Taylor DA, Vojvodic RW, Yang PC, Moyé LA; Cardiovascular Cell Therapy Research Network. Phase II clinical research design in cardiology: learning the right lessons too well: observations and recommendations from the Cardiovascular Cell Therapy Research Network (CCTRN). Circulation. 2013 Apr 16;127(15):1630-5. doi: 10.1161/CIRCULATIONAHA.112.000779.

Nazarian S, Halperin HR. How to perform magnetic resonance imaging on patients with implantable cardiac arrhythmia devices. Heart Rhythm. 2009 Jan;6(1):138-43. doi: 10.1016/j.hrthm.2008.10.021. Epub 2008 Oct 22. Review.

Bolli R, Hare JM, March KL, Pepine CJ, Willerson JT, Perin EC, Yang PC, Henry TD, Traverse JH, Mitrani RD, Khan A, Hernandez-Schulman I, Taylor DA, DiFede DL, Lima JAC, Chugh A, Loughran J, Vojvodic RW, Sayre SL, Bettencourt J, Cohen M, Moyé L, Ebert RF, Simari RD; Cardiovascular Cell Therapy Research Network (CCTRN). Rationale and Design of the CONCERT-HF Trial (Combination of Mesenchymal and c-kit(+) Cardiac Stem Cells As Regenerative Therapy for Heart Failure). Circ Res. 2018 Jun 8;122(12):1703-1715. doi: 10.1161/CIRCRESAHA.118.312978. Epub 2018 Apr 27.

• Responsible Party: Barry R Davis, Professor of Biostatistics, The University of Texas Health Science Center, Houston
• ClinicalTrials.gov Identifier: NCT02501811
• Other Study ID Numbers: HSC-SPH-15-0413; 5UM1HL087318 ( U.S. NIH Grant/Contract )
• First Posted: July 17, 2015
• Last Update Posted: October 27, 2020
• Last Verified: October 2020

Keywords provided by Barry R Davis, The University of Texas Health Science Center, Houston:

Heart Failure; Ischemia; Autologous Stem Cells; LV dysfunction; Mesenchymal Stem Cells; c-kit+ Cells; Combination Cell Therapy; LV function; Functional status

Additional relevant MeSH terms:

Heart Failure; Cardiomyopathies; Heart Diseases; Cardiovascular Diseases; Plasma-lyte 148; Ophthalmic Solutions; Pharmaceutical Solutions